Carotuximab, referred to as TRC105 while DE-122, represents a emerging antibody-drug conjugate ADC currently evaluated for combating various cancerous conditions. This distinct molecule targets a specific antigen, expressed on cancer cells, delivering a potent cytotoxic substance directly inside the diseased area. Early clinical trials have shown p

Vadastuximab tedelpar antibody-drug conjugate representing a crucial advancement in the management of acute myeloid leukemia (AML). This pioneering therapy precisely targets CD33, a protein frequently expressed on leukemic blasts . The mechanism involves binding to CD33, causing both direct cytotoxicity and improved immune-mediated destruction of c

The arrival of amivantamab presents a important step forward for individuals battling cancers with c-MET dysregulation. This innovative molecule, a precise agent of both MET kinase and also human epidermal growth factor receptor 2 (HER2), showed preliminary efficacy in research trials, particularly in patients whose tumors harbor exhibitable c-MET